Schlagwortarchiv für: Publikationen: Prof. Dr. rer. nat. Volker Schirrmacher
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-12-01 / Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-3
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-12-01 / Ann. Surg. 2006 Dec;244(6):986-92; discussion 992-32006-12-01 00:00:002020-06-23 09:36:05Tumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-38
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-07-15 / Int. J. Cancer 2006 Jul;119(2):328-382006-07-15 00:00:002020-06-23 09:36:30Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-672006-02-01 00:00:002020-06-23 09:36:57A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-08-01 / Int. J. Oncol. 2005 Aug;27(2):377-842005-08-01 00:00:002020-06-23 09:37:35Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-31 / Vaccine 2005 Mar;23(19):2439-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-31 / Vaccine 2005 Mar;23(19):2439-532005-03-31 00:00:002020-06-23 09:38:03T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-3032005-03-01 00:00:002020-06-23 09:38:35Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-02-01 / Int. J. Oncol. 2005 Feb;26(2):431-92005-02-01 00:00:002020-06-23 09:39:16Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-612004-11-01 00:00:002020-06-23 09:39:52Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-10-30 / Cancer Immunol. Immunother. 2005 Jun;54(6):587-982004-10-30 00:00:002020-06-23 09:40:23Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-81
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-09-27 / J. Clin. Oncol. 2004 Nov;22(21):4272-812004-09-27 00:00:002020-06-23 09:41:00Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
